Streamlining Neurology Prior Authorizations with Surescripts Integration

Klivira's advanced **neurology Surescripts integration** empowers clinics and health systems to dramatically accelerate prior authorization workflows for complex neurological treatments.

Neurology practices face a uniquely high volume of prior authorizations for specialty drugs, advanced imaging, and interventional procedures. Managing these PAs manually strains revenue cycles and delays patient access to critical therapies. Klivira leverages Surescripts ePA capabilities to automate and streamline these intricate processes, ensuring faster approvals and improved operational efficiency.

The Challenge: High-Volume Specialty Drug PAs in Neurology

Neurology prior authorization is heavily concentrated in high-cost, high-complexity specialty drugs. These include MS disease-modifying therapies (DMTs), CGRP migraine biologics, Alzheimer's disease therapeutics, and treatments for spinal muscular atrophy (SMA) and ALS. Each often requires extensive clinical documentation, adherence to step therapy protocols, and frequent re-authorizations, creating significant administrative overhead.

Accelerating Prior Authorization for Key Neurology Therapies via Surescripts ePA

Klivira's **neurology Surescripts integration** directly addresses the burden of specialty drug PAs. By connecting prescribers, pharmacies, PBMs, and health plans, the platform facilitates electronic prior authorization (ePA) submissions for medications that frequently trigger PA requirements. This includes high-efficacy MS DMTs, anti-amyloid antibodies for Alzheimer's, and CGRP monoclonal antibodies for migraine prevention.

Neurology Medications and Conditions Benefiting from Surescripts ePA

  • **MS Disease-Modifying Therapies (DMTs)**: Ocrelizumab, ofatumumab, natalizumab, and oral DMTs often require stringent PA.
  • **Alzheimer's Disease Therapeutics**: Lecanemab, donanemab, and similar anti-amyloid antibodies with complex documentation needs.
  • **Migraine Prevention Biologics** (CGRP monoclonal antibodies): Erenumab, fremanezumab, galcanezumab, eptinezumab, and oral gepants.
  • **Spinal Muscular Atrophy / ALS Treatments**: Nusinersen, onasemnogene abeparvovec, risdiplam, edaravone, tofersen.
  • **Epilepsy Specialty Drugs**: Cenobamate, brivaracetam, lacosamide, cannabidiol for specific indications.

Navigating Documentation and Step Therapy with Integrated Workflows

Neurology prior authorizations are often denied due to gaps in documentation or non-compliance with step therapy. Klivira's integration with Surescripts ePA streamlines the submission of required clinical data, such as McDonald criteria for MS, amyloid confirmation for AD, or prior preventive trials for CGRP migraine. The platform embeds AAN Practice Guidelines-aware logic to guide staff through payer-specific requirements, mitigating common denial reasons like step therapy for MS DMTs or amyloid biomarker confirmation gaps for AD anti-amyloid antibodies.

Klivira's Intelligent Automation for Neurology ePA

Beyond Surescripts ePA, Klivira's platform provides comprehensive automation tailored for neurology. This includes tracking periodic re-authorization for chronic treatments, such as MS DMTs, and managing the documentation for ongoing MRI monitoring requirements often associated with these therapies. Our solution integrates with your EMR to pull relevant clinical data, auto-populating forms and reducing manual data entry for both initial and renewal authorizations.

Frequently asked questions

How does Surescripts integration specifically help with prior authorizations for MS DMTs?

Surescripts ePA facilitates the electronic submission of prior authorization requests for MS disease-modifying therapies. Klivira augments this by automating the collection of necessary clinical evidence, such as McDonald criteria, EDSS scores, and prior DMT trials, directly from the EMR, ensuring compliance with payer step therapy requirements and AAN guidelines.

Can Surescripts ePA handle the complex documentation for Alzheimer's anti-amyloid therapies?

While Surescripts ePA provides the electronic channel for submission, Klivira's platform specializes in gathering the complex documentation required for Alzheimer's anti-amyloid antibodies. This includes confirming clinical AD diagnosis, amyloid confirmation (PET or CSF), MRI for ARIA screening, and ApoE genotyping, which are critical for approval and often a source of denial if incomplete.

Does Surescripts integration also cover prior authorizations for advanced imaging like brain MRIs?

Surescripts ePA is primarily designed for prescription medications. Prior authorizations for advanced imaging, such as brain MRIs or amyloid PET scans, typically fall under medical benefit PAs and are processed through different channels (e.g., X12 278 transactions or payer portals). Klivira's platform supports these medical benefit PAs independently, integrating with EMRs and various payer channels to manage all types of neurology authorizations.

How does Klivira address the need for periodic re-authorizations in neurology via Surescripts?

Many neurology specialty drugs, like MS DMTs and CGRP biologics, require periodic re-authorization. Klivira's system tracks these re-authorization cycles, proactively initiating the ePA process through Surescripts before expiration. It leverages stored patient data and updated clinical information from the EMR to streamline renewal submissions, minimizing treatment disruptions.

What EMR touchpoints are integrated for neurology Surescripts ePA?

Klivira integrates with your EMR via SMART on FHIR and other APIs to pull relevant patient demographics, diagnoses, medication history, and clinical notes directly into the Surescripts ePA workflow. This automation reduces manual data entry, ensures accuracy, and accelerates the submission of prior authorization requests for neurology drugs ordered within the EMR.

Related coverage

Other neurology prior auth workflows

Ready to automate this workflow for this specialty?

See how Klivira automates prior authorizations for your team.

Request a demo